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ABSTRACT 
Bone marrow (BM) transfer from flagellin-treated mice has been reported to improve the survival 
of lethally-irradiated mice. Although the mechanism for flagellin’s antiviral and antibacterial effects have 
been elucidated, there remains a gap in knowledge regarding its radioprotective effects.  
Here, we report that flagellin treatment results in a 5-fold increase in the proliferation of Lin-Sca-
1+C-Kit+(LSK) cells, a heterogeneous stem and multipotent cell population in BM, with the most striking 
increase within the ST-HSC, MPP2 and MPP3 subpopulations. Furthermore, the presence of TLR5 but 
not NLRC4 on radiosensitive, non-LSK cells in BM was both sufficient and necessary for the observed 
phenomenon. Finally, adoptive transfer of MPP3 cells along with an insufficient amount of whole bone 
marrow cells (WBM) to lethally-irradiated mice significantly improved their survival, recapitulating the 
effects of Whole bone marrow from flagellin-treated mice. 
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1 INTRODUCTION  
An important role for innate immune cells is the recognition of antigenic molecules, otherwise 
known as Pathogen Associated Molecular Patterns (PAMPs)1,2. The recognition of specific PAMPs 
allows immune cells to carry out effector functions that result in tailoring of subsequent immune reactions 
to the relevant antigen1,2. One such PRR is the membrane-bound TLR5, which recognizes flagellin as its 
cognate PAMP1. Flagellin is also recognized by the intracellular NLRC4 inflammasome 3. Although 
TLR5 and NLRC4 recognize the same molecule, they result in different downstream signaling events. 
Specifically, TLR5 signaling leads to the activation of NFB signaling, resulting in the transcription of 
pro-inflammatory cytokines3–8. NLRC4 signaling on the other hand, results in the activation of caspase I, 
which cleaves inactive precursors of  IL-1 and IL-18 into their active forms3,4. 
In mice, flagellin treatment has been shown to provide broad spectrum protection from viruses, 
bacteria, chemicals and radiation without the overt inflammatory pathology associated  with LPS 
treatment1,9. Flagellin treatment protected C57BL/6 mice from rotavirus infection and also cured chronic 
rotavirus infection in a TLR5, NLRC4, IL-18 and IL-22-dependent manner4. In addition, flagellin 
treatment protected pre-treated mice from S. typhimurium, DSS-induced colitis, and increased the survival 
rate of lethally irradiated mice1. While the mechanism of flagellin-induced protection has been mostly 
elucidated for some of these conditions- chronic rotavirus infection, for instance- the mechanism that 
confers irradiation protection remains undefined.  
Lethal irradiation of mice results in the death of radiosensitive hematopoietic cells, which 
constitute a significant proportion of mature hematopoietic cells and bone marrow stem cells10. Survival 
from this challenge is predicated on the ability of Hematopoietic Stem Cells (HSCs) to rapidly repopulate 
hematopoietic lineages, particularly neutrophils10. In characterizing HSCs, the phenotype Lin- Sca-1+ C-
kit+ has been previously documented as a rare heterogeneous population containing Hematopoietic stem 
cells (HSCs) and Multipotent progenitors (MPPs) which account for about 0.5% of cells in the bone 
marrow11.These cells are capable of differentiating into other cell types, eventually giving rise to the 
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different hematopoietic cell lineages. So far, long-term HSCs (LT-HSC) have been identified as the most 
long-lived BM stem cells, which are capable of self-renewal in addition to differentiation. The LSK 
population contains other cell types including short-term HSCs (ST-HSC) and multipotent progenitors 
(MPPs) with increasingly limited differentiation potential and lifespan12–15.  
We hypothesized that flagellin’s radioprotective effects may results from its ability to prime bone 
marrow cells to more efficiently repopulate hematopoietic lineages. This hypothesis was instigated by 
observations that flagellin treatment resulted in such a large increase in the number of neutrophils in 
peripheral blood, that traditional depletion methods (anti-Ly6G) could not eliminate them. We 
hypothesized that neutrophil recruitment alone would not account for this extent of neutrophilia and, 
hence, flagellin-induced changes to bone marrow stem cell proliferation may be involved.  
The study presented herein outlines our investigations into flagellin’s effect on bone marrow stem 
cell populations and the impact of these changes on the survival of lethally irradiated mice. We report that 
flagellin treatment induced the proliferation of the heterogeneous LSK cell population, most significantly 
ST-HSC, MPP2 and MPP3 cells. This increased proliferation was dependent on TLR5 but not NLRC4 on 
radiosensitive non-LSK cells in the bone marrow. Finally, we report that the radioprotective effects of 
flagellin-treated bone marrow cells were successfully replicated by adoptively transferring MPP3 cells 
(from flagellin-treated mice) along with an insufficient amount of bone marrow cells from untreated mice 
to lethally irradiated recipient mice. 
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2 MATERIALS AND METHODS 
2.1 Mice 
Mouse experiments were approved under protocol A14033 (102117) by the Georgia State University 
Institutional Animal Care and Use Committee (IACUC). TLR5-/- mice, generated by Dr. Shizuo Akira 
(Osaka University, Japan), were backcrossed with C57BL/6 mice for 10 generations to give rise to   
TLR5-/- mice on a C57BL/6 background. C57BL/6 mice (WT CD45.1 and CD45.2) were purchased from 
Jackson Laboratories (Bar Harbor, ME), while NLRC4-/- mice were purchased from Genentech Inc. (San 
Francisco, CA). TLR5-/-NLRC4-/- mice were generated as previously described16. 
2.2 Bone marrow cell collection  
Both femurs of sacrificed mice were removed, flushed with ‘Complete’ RPMI (RPMI 1640 + 5% FBS + 
100 U/ml penicillin + 100 μg/ml streptomycin + 2M L-glutamine) and filtered through 70μm cell 
strainers. RBC lysis buffer (NH4Cl + KHCO3 +EDTA) was used to lyse red blood cells for 3 minutes, 
after which they were re-filtered as before. Following lysis, cells were washed with cold PBS, spun down 
(300G, 10minutes) and resuspended in FACS buffer (0.5% BSA + 1mM EDTA in PBS) or cell culture 
medium. 
2.3 Preparation of blood leukocytes  
Mice were bled retro-orbitally into heparinized tubes. Blood was suspended in RBC lysis buffer for 10 
minutes, after which cells were washed with PBS twice, filtered through a 70μm cell strainer and pelleted 
(300G, 10 minutes). 
2.4 Preparation of flagellin 
As previously described17, the flagellin isoform FliC was isolated from FljB-/- S. typhimurium 
(SL3201fljB-). The bacterial culture supernatant was centrifuged and flagella were then broken down to 
their monomeric form by boiling. Flagellin monomers were HPLC-purified using polymixin B agarose, 
S-sepharose and Q-sepharose. The purity of this flagellin was verified by assaying gene expression in 
4 
NLRC4-/- TLR5-/- mice (RT-PCR and microarray in response to treatment with this purified FliC. The 
product was shown to not contain innate immune agonists other than FliC. 
2.5 In vivo and ex vivo flagellin treatment 
Six to eight-week old Mice were treated with PBS or 20g of FliC intraperitoneally (i.p) and sacrificed 
after 15 hours. In cell proliferation assays, mice were treated with 10mg BrdU for 1 hour prior to 
sacrifice. In ex vivo experiments, cell cultures contained 1x107 cells in 20ml of complete RPMI alone or 
containing 50ng/ml FliC for 15 hours before being pelleted (300g, 10 minutes) and analyzed. For ex vivo 
proliferation assays, cultures were treated with 10μM BrdU for one hour prior to being pelleted.  
2.6 Flow cytometry analysis and cell sorting 
Before FACS staining, cell suspensions were incubated with Fc Block (2.4G2) at 4oC. The panel used for 
flow cytometry staining included: Lineage Cocktail- biotin-BB515 (Biolegend, San Diego, CA), Sca-1-
APC (e-bioscience, Santa Cara, CA), c-Kit- Pacific Blue (e-bioscience), CD34- Alexa Fluor 700 (e-
bioscience), Flt-3- PE (e-bioscience), CD48- PE-Cy7 (e-bioscience), CD150- BV655 (Biolegend). 
Samples were analyzed on a BD LSR Fortessa (BD Biosciences, San Jose, CA). In proliferation assays, 
intracellular BrdU and 7-AAD staining was carried out after extracellular staining. The kit and protocol 
from BD Biosciences (San Jose, CA) were used. Flow Cytometer Cell Counting beads (Thermofisher 
Scientific, Waltham, MA) were included in each sample in order to facilitate cell counting. For cell 
sorting, the following panel was used: Lineage Cocktail- BB515, Sca-1-PerCP, c-Kit- Pacific Blue, Flt-3- 
PE, CD48- PE-Cy7, CD150- BV655, and sorting was carried out on a Sony SH-800 Cell Sorter (Sony 
Biotechnologies, San Jose, CA).   
2.7 Generation of chimeras  
Mice were subjected to total body irradiation with a lethal dose of X-rays (8.5Gy) from an RS-2000 
irradiator (Rad Source Technologies), following which they received bone marrow cells from donor mice 
as indicated in the results and figures. Donor bone marrow was extracted as described above and then and 
administered intravenously (I.V) via tail-vein injection to recipient mice. Donor and recipient mice 
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expressed different CD45 alleles (CD45.1 or CD45.2), in order to facilitate distinction of cell origin 
during flow cytometry analysis. Mice were maintained in sterile cages and provided with 2mg/ml 
Neomycin water and autoclave-sterilized food for 2 weeks. In the MPP3 sorting studies, mice were 
administered indicated amounts of whole bone marrow cells in addition to FACS-sorted MPP3 cells and 
maintained in the same manner as chimeras described above. MPP3 differentiation study mice were bled 
at the indicated time points and samples analyzed by flow cytometry, while MPP3 survival study mice 
were tracked for at least 30 days post-transplantation. 
2.8 Short-term repopulation assay 
Test donor bone marrow cells were CD45.1+ while competitor cells were CD45.2+, both from WT 
C57BL/6 mice. Recipient mice (CD45.1+) were lethally irradiated as previously described (X-ray, 8.5Gy), 
following which they received 2x105 competitor cells along with 1x105 or 1x106 test donor cells. Mice 
were housed under sterile conditions and provided with autoclave-sterilized water (2mg/ml neomycin) 
and autoclaved food. At 4 weeks post-transplantation, the blood of these mice was analyzed by flow 
cytometry. Peripheral repopulation was calculated based on CD45.1+ and CD45.2+ cells and on lymphoid 
(CD11b-) and myeloid (CD11b+) cells using the following formula18–20: 




3.1 Flagellin treatment induces the proliferation of LSK cells in bone marrow 
Flagellin treatment and bone marrow from flagellin-treated mice have been shown to protect mice from 
lethal irradiation9. In addition, we observed that flagellin treatment resulted in a significant increase in the 
number of neutrophils in the blood, to such extent that we were unable to deplete these cells via 
traditional methods (anti-Ly6G). These lines of evidence led to the hypothesis that flagellin could 
possibly prime bone marrow stem cells in a manner that enabled them to more efficiently proliferate or 
differentiate into certain cell types. To test this hypothesis, we assayed the proliferation of HSCs in the 
bone marrow of flagellin-treated mice by flow cytometry. These HSCs are delineated by the phenotype 
Lin- Sca-1+ C-Kit+ (LSK).  
Figure 1. Flagellin treatment induces the proliferation of LSK cells in bone marrow: in vivo. Mice were administered 20g of flagellin in PBS or PBS alone intraperitoneally (i.p.). After 15 hours, 10mg of BrdU was administered (i.p.) and mice were sacrificed 1 hour afterwards. Bone marrow of these mice were then stained and assayed by flow cytometry. A) Flow cytometry plot depicting gated Lin- cells, LSK cells and BrdU incorporation in the LSK cell population from a mouse with a typical response. Graphs show average: B) LSK percentage in BM, C) LSK cell number in BM, and D) LSK cell BrdU incorporation percentage from one experiment. Error bars = Standard error of the mean (SEM). Group means were compared by unpaired t-test: ***, P ≤ 0.001; **, P < 0.01.  
 Our results showed that 15 hours after flagellin treatment, the percentage and absolute number of LSK 
cells in the BM of wild-type (WT) mice was about 4-fold higher than in untreated mice (fig. 1). The 
number of LSK cells in the S-phase was also increased by about 5 times in the flagellin-treated mice. 
Next, we sought to determine whether this phenomenon would occur under ex vivo conditions. To this 
end, murine bone marrow was collected from WT mice and cultured in the presence of flagellin for 15 
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hours. The results of our flow cytometry assay showed LSK cell percentages, absolute numbers and 
percentage in S-phase to be increased, although to a lesser extent than in the in vivo experiment (fig. 1). 
Figure 2. Flagellin treatment induces the proliferation of LSK cells in bone marrow: ex vivo. Whole BM was aspirated from the femurs of mice and cultured in medium with or without 50ng/ml flagellin. After 15 hours, cultures were treated with 10M BrdU for 1 hour following which cells were stained and assayed by flow cytometry. A) Flow cytometry plot depicting gated Lin- cells, LSK cells and BrdU incorporation in the LSK cell population from a mouse with a typical response. Graphs show average: B) LSK percentage in BM, C) LSK cell number in BM, and D) LSK cell BrdU incorporation percentage from one experiment. Error bars = SEM. Group means were compared by unpaired t-test: ***, P ≤ 0.001.  
3.2 Flagellin treatment induces proliferation of ST-HSC and MPPs in bone marrow 
The bone marrow LSK cell population is a heterogeneous one comprised of subsets of cells with varying 
self-renewal and differentiation properties. While we have established that flagellin treatment does in fact 
increase the proliferation of the LSK population, it became pertinent to our investigation to explore 
whether flagellin preferentially influences the proliferation of specific LSK subsets. These functionally 
distinct subsets may be differentiated through flow cytometry assays that employ the use of CD34, Flt3, 
and the Signaling Lymphocyte Activation Molecule (SLAM) code markers CD150 and CD48, in addition 
to Lineage (lin), Sca-1 and C-Kit. With the use of these cell markers, LT-HSC cells are categorized as 
CD34- Flt3- CD150+ CD48-, ST-HSC as CD34+ Flt3- CD150- CD48-, MPP1 cells as CD34+ Flt3- CD150+ 
CD48-, MPP2 cells as CD34+ Flt3- CD150+ CD48+, MPP3 cells as CD34+ Flt3- CD150- CD48+ and MPP4 
cells as CD34+ Flt3+ CD150- CD48+.  
We observed that there was an increase in the percentage, cell number and S-phase percentage in several 
LSK cell subpopulations upon flagellin treatment. The most striking of these were Short-Term 
Hematopoietic Stem Cells (ST-HSC) and Multipotent Progenitor 3 (MPP3) cells. Compared to untreated 
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mice, there was a 4-fold increase in total ST-HSC number and 4-fold increase in percentage of ST-HSC in 
the S-phase. Concurrently, there was a 9-fold increase in total MPP3 cell number and 2-fold increase in 
percentage of MPP3 cells in the S-phase. There were also significant increases in the number of MPP1 
and MPP4 cells, with an increase in the percentage of MPP4 cells in the S-phase. There were no increases 
in the number of LT-HSC cells or in the percentage of these cells in the S-phase. Ex vivo treatment of 
murine BM cells revealed a similar trend, albeit to a lesser degree than the in vivo treatment. 
 Figure 3. Flagellin treatment induces proliferation of ST-HSC and MPPs in bone marrow. Mice were treated with flagellin and BrdU as before. BM from femurs were stained and analyzed by flow cytometry. Flow cytometry plots depicting gating and BrdU incorporation of: A) ST-HSC, MPP1, MPP2 and MPP3 cells; B) MPP4 cells C) LT-HSC cells from a mouse with a typical response. Graphs depicting average: D) LSK cell number in BM, E) Number of LSK subtype cells in BM, and F) BrdU incorporation percentage in LSK subtype cell populations from one experiment. Error bars = SEM. Group means were compared by unpaired t-test: ***, P ≤ 0.001; **, P < 0.01; ns= not significant.  
3.3 Flagellin-induced LSK cell proliferation is mediated by TLR5 but not NLRC4. 
Flagellin is recognized by TLR5 and NLRC4 in both mice and humans. While these two receptors 
recognize the same molecule, their downstream signaling cascades differ1–9,16. Therefore, it was important 
to determine whether flagellin-induced LSK proliferation was reliant on recognition by one or both 
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receptors. To this end, we assessed the proliferation of LSK cells in NLRC4-/- (N4KO), TLR5-/- (T5KO) 
and NLRC4-/-TLR5-/- (N4T5DKO) mice, in response to flagellin treatment. We observed that LSK 
proliferation in N4KO mice was similar to that observed in WT mice, with increased LSK cell percentage  
number and proliferation. The proliferation of LSK cells in T5KO and N4T5DKO, on the other hand, was 
almost completely eliminated (fig 3). In these mice, LSK cell percentage number and proliferation rates 
remained essentially unchanged in flagellin treated mice 15 hours post-treatment. 
 
3.4 Flagellin-induced LSK cell proliferation requires the expression of TLR5 on radiosensitive 
bone marrow or bone marrow-derived cells 
Although we had determined TLR5 to be the pertinent receptor for flagellin-induced LSK proliferation, it 
remained unclear how the systemic flagellin signal was transmitted to LSK cells. It was possible that the 
signal was received by radiosensitive BM or BM-derived cells within the bone marrow or that these cells 
were radioresistant cells of a similar origin. To investigate these possibilities, we generated two kinds of 
chimeras and examined LSK proliferation in these mice once challenged with flagellin. The first kind of 
Figure 4. Flagellin-induced LSK cell proliferation is mediated by TLR5 but not NLRC4. Wildtype (WT), N4T5-DKO, T5 KO and N4KO mice were treated with flagellin and BrdU and their BM stained and analyzed as before. A) Flow cytometry plot depicting Lin- cells, LSK cells and BrdU incorporation of LSK cells in WT and N4T5-DKO mice. Graphs showing average: B, E) LSK cell percentage in BM; C, F) LSK cell number in BM of WT, N4T5-DKO, T5 KO and N4 KO mice. D) BrdU incorporation percentage of LSK cells in BM of WT and N4T5DKO mice. Error bars = SEM. Group means were compared by unpaired t-test: ***, P ≤ 0.001; **, P < 0.01; *, P< 0.05; ns= not significant.  
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chimera was generated by adoptively transferring CD45.2+ WT whole BM cells to lethally irradiated 
CD45.1+ T5KO mice. These mice would, therefore, express NLRC4 and TLR5 only in radiosensitive BM 
and BM-derived cells, but not in other cell types. The second set of chimeras, which would express TLR5 
and NLRC4 in all cells except radioresistant BM and BM-derived cells, were lethally irradiated CD45.2+ 
WT mice which received CD45.1+ T5KO whole BM cells. These mice. After a recovery period of 8 
weeks, these chimeras were challenged with flagellin as before.  
We observed LSK proliferation in the mice that expressed TLR5 and NLRC4 only on radiosensitive BM 
and BM-derived cells (first set of chimeras) but not in those that expressed the receptors only in other cell 
types.  
 
3.5 Flagellin induces LSK cell proliferation through the activation of TLR5 on non-LSK cells 
Although we had determined that the presence of TLR5 on radiosensitive BM and BM-derived cells was 
required for flagellin-induced LSK proliferation, it was still unclear whether systemic flagellin directly 
activated LSK cells themselves (which are radiosensitive BM cells) or acted indirectly through an 
intermediate TLR5-bearing cell type. 
Figure 5. Flagellin-induced LSK cell proliferation requires the expression of TLR5 on radiosensitive bone marrow or bone marrow-derived cells. Bone marrow chimeras were generated and treated with flagellin as previously described. A) Average LSK cell percentage in BM, B) Average LSK cell number in BM. Error bars = SEM. Group means were compared by unpaired t-test: ***, P ≤ 0.001; ns= not significant.  
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Accordingly, we generated mixed BM chimeras in which the recipient mice were lethally irradiated 
N4T5DKO (CD45.1+) mice that received whole BM from both N4T5DKO (CD45.1+) and WT (CD45.2+) 
in a 1:1 ratio. After 8 weeks, we challenged these mice with flagellin and assayed their bone marrow cells 
by flow cytometry. Upon analysis, we observed identical levels of increase in LSK percentage, number 
and proliferation among cells of WT and N4T5DKO origin. These LSK levels, although increased were 
still lower than those observed in flagellin-treated WT mice.  
 
As a complement, we also carried out a mixed cell culture containing equal amounts of whole bone 
marrow cells from WT CD45.1+ mice and N4T5DKO CD45.2+ mice. Cultures were incubated with 
50ng/ml of Flagellin for 15 hours, after which cells were pelleted, stained and analyzed by flow 
Figure 6. Flagellin induces LSK cell proliferation through the activation of TLR5 on non-LSK cells: in vivo Mixed bone marrow chimeras were generated and treated with flagellin or PBS after 8 weeks. Graphs depict average A) LSK cell percentage in BM, and B) LSK cell number in BM. Error bars = SEM. Group means were compared by unpaired t-test: ***, P ≤ 0.001; **, P < 0.01. 
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cytometry. The results obtained in the ex vivo (culture) were in accord with those observed in the in vivo 
mixed chimera.   
 
3.6 Flagellin-treated bone marrow cells are myeloid-biased 
As previously stated, flagellin’s ability to rescue lethally irradiated mice may lie in its ability to alter the 
differentiation potential of bone marrow stem cells. Therefore, it would be rational to expect that 
flagellin-treated bone marrow may present with an enhanced ability to replenish ablated hematopoietic 
cells.  Accordingly, we carried out a classical repopulation assay which compared the repopulation 
capacity of flagellin treated bone marrow to untreated bone marrow in a lethally irradiated mouse. 1x105 
or 1x106 test donor BM cells (CD45.1+) from flagellin-treated mice, along with 2x105 competitor BM 
cells (CD45.2+) from untreated mice were transferred to CD45.1+ recipient mice. From this experiment, 
we observed that there was no difference in the repopulation ability of flagellin-treated whole bone 
marrow in comparison to untreated whole bone marrow. However, we did observe that flagellin treated 
Figure 7.  Flagellin induces LSK cell proliferation through the activation of TLR5 on non-LSK cells: in vivo. WT and N4T5-DKO BM cells were mixed (1:.1 ratio) and cultured with or without 50ng/ml flagellin. Ater 15 hours, cultures were treated with 10mM BrdU for 1 hour, following which cells were pelleted, stained and analyzed by flow cytometry. A) Flow cytometry plot depicting total LSK cells in culture, CD45.1+ and CD45.2+ LSK cells and their respective BrdU incorporation percentage. B) Graphs showing average B) LSK cell percentage in BM, C) LSK cell number in BM and D) Brdu incorporation of LSK cells in BM. Error bars = SEM. Group means were compared by unpaired t-test: ***, P ≤ 0.001. 
13 
bone marrow gave rise to a higher proportion of myeloid cells and lower proportion of lymphoid cells 
than untreated whole bone marrow cells.  
 
3.7 MPP3 cells from flagellin-treated mice transiently repopulate the neutrophil compartment  
Among the LSK subsets activated by flagellin treatment, we observed the greatest increase in 
proliferation within the MPP3 subset (9-fold increase in number). In light of this result, we though it 
prudent to conduct functional analyses of the proliferation and differentiation capabilities of these 
flagellin-expanded MPP3 cells in lethally irradiated mice. Consequently, we adoptively transferred 2000 
MPP3 cells (CD45.2+) from flagellin-treated mice, along with 4x105 competitor whole bone marrow cells 
(CD45.1+) from untreated mice to lethally irradiated mice. (CD45.1+). The expression of different CD45 
alleles, allowed for the differentiation of cellular origin during FACS analysis. On days 14, 28 and 60, the 
chimeras were bled and their blood analyzed. From these analyses, we observed that the transferred 
MPP3 cells almost exclusively gave rise to myeloid cells (CD11b+) by day 14. Upon further analysis, 
Figure 8. Flagellin-treated bone marrow cells are myeloid-biased. 1x105 or 1x106 whole bone marrow cells from flagellin or PBS treated mice were used as the test donor cells in a classical repopulation assay. Mouse blood leukocytes were analyzed by flow cytometry at 4 weeks post-transfer. A) Average calculated repopulation unit (RU) of test donor cells in peripheral blood. B) Average calculated total, myeloid and lymphoid RU of 1x105 test donor cells in peripheral blood. 
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majority of these myeloid cells were determined to be neutrophils (Ly6G+ CD11b+). By day 28, there was 
a small decline in the number of MPP3-derived myeloid cells, accompanied by an increase in lymphoid 
cells (CD11b-) of the same origin. On day 60, there was a further increase in the percentage of lymphoid 
cells, while the majority of myeloid cells had been lost. 
 
3.8 MPP3 cells from flagellin-treated mice improve the survival of lethally-irradiated mice 
In continuation of our exploration of the functional capacity of MPP3 cells, we sought to determine the 
impact of MPP3 administration on the survival of lethally-irradiated mice. Accordingly, we adoptively 
transferred 5000 MPP3 cells from flagellin-treated mice, along with 1x105 whole BM cells from untreated 
mice to lethally irradiated mice. Control mice received 1x105 whole BM cells alone, an amount which we 
had previously determined to be insufficient to rescue lethally-irradiated mice. The survival of these mice 
Figure 9. MPP3 cells from flagellin-treated mice transiently repopulate the neutrophil compartment. 2000 FACS-sorted MPP3 cells (CD45.2+) from flagellin-treated mice were transferred with 4x105 competitor whole bone marrow cells (CD45.1+) to CD45.1+ recipient mice. Control mice received only competitor cells. Blood of these mice were stained and analyzed by flow cytometry at 14, 28 and 60 days post transfer A) Flow cytometry plot showing gated CD45.1+ and CD45.1- cells.  
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was tracked over 30 days. Mice that received MPP3 cells showed 100% survival by day 30, less than 40% 
of those that received BM without MPP3 survived.  
  
Figure 10. MPP3 cells from flagellin-treated mice improve the survival of lethally-irradiated mice. 5000 FACS-sorted MPP3 cells from flagellin-treated mice were transferred to lethally irradiated recipient mice along with 1x106 whole bone marrow cells from untreated mice. Control mice received whole bone marrow cells alone. Mouse survival was tracked for 30 days   
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4 DISCUSSION  
Flagellin treatment has been shown to protect mice against a host of pathologies, including 
radiation-induced lethality. Specifically, transplantation of bone marrow cells from flagellin-treated mice 
to irradiated mice or treatment of mice with flagellin prior to irradiation was shown to increase the 
survival of these mice relative to untreated controls1,9. While flagellin-mediated radiation protection was 
reported to be dependent on liver hepatocytes1, not much else is known about this phenomenon. In light 
of this gap in knowledge, the aim of our study was to investigate the underlying mechanism involved in 
flagellin-mediated irradiation protection in mice. 
We hypothesized that flagellin’s ability to rescue lethally irradiated mice may reflect its ability to 
impact the proliferative state of bone marrow stem cells. Our hypothesis was motivated not only by 
flagellin’s radioprotective ability but also because of the substantial increase in blood and intestinal7,17 
neutrophils observed upon flagellin treatment (data not shown). As a start to our investigations, we sought 
to determine how in vivo and ex vivo flagellin treatment impacted the frequency of different bone marrow 
stem cell populations. Under non-inflammatory conditions, majority of stem cells contained in bone 
marrow niches are quiescent21,22 We found that systemic flagellin treatment resulted in the increased 
proliferation of Lin-Sca-1+C-Kit+ (LSK) bone marrow cells, among which the MPP3 (Multipotent 
Progenitor 3) subset was most striking. There was however no increase in the proliferation of the LT-HSC 
(Long-Term Hematopoietic Stem Cell) subset. This result was in keeping with the results of our Classical 
Repopulation assay, which showed that the long-term repopulation capacity of flagellin-treated bone 
marrow cells did not significantly differ from that of PBS-treated cells when adoptively transferred to 
lethally irradiated mice. Rather, flagellin-treated bone marrow displayed a bias towards myeloid cell 
differentiation. This myeloid bias was commensurate with our results that flagellin-activated MPP3 cells, 
which were the most significantly activated LSK subset, predominantly gave rise to. Although the 
presence of MPP3 cells and their progeny appears to be vital for flagellin-mediated radiation survival, 
these cells are non-renewing and relatively short-lived, present within the first month post-transplantation 
and consistently diminishing in the following weeks. As the expedient generation of myeloid cells, 
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particularly neutrophils post-irradiation is an important indicator of post-irradiation survival,10 this bias 
appears to, at least in part, explain the ability of flagellin-expanded bone marrow cells to confer a survival 
advantage to lethally irradiated mice. That this improved survival could be recapitulated by a relatively 
small number of transplanted MPP3 cells is not altogether surprising, since these cells make up a small 
percentage of bone marrow cells, which give rise to an exponentially greater number of effector cells. In 
effect, flagellin-treated bone marrow may owe its radioprotective capabilities to its ability to more rapidly 
or efficiently repopulate ablated myeloid cells, especially neutrophils. 
As we had now determined that flagellin treatment did, in fact, impact the stem and progenitor 
cell populations in the bone marrow, we next sought to investigate how the systemic flagellin treatment 
was relayed to bone marrow cells. Although hepatocytes had been previously implicated in flagellin-
mediated radiation protection1, our observations contrasted with this report. Specifically, we observed an 
increased proliferation of bone marrow LSK cells in flagellin-treated Alb-Cre TLR5fl/fl mice, (which do 
not express TLR5 in previously-implicated hepatocytes) to a similar extent as that observed in wild type 
mice (data not shown). From this, we concluded that TLR5-bearing liver hepatocytes were not required 
for LSK proliferation in response to flagellin. Following this observation, further experiments (in vivo 
and ex vivo) showed that flagellin-induced LSK proliferation relied on TLR5 expressed by radiosensitive 
bone marrow-derived cells. Although LSK cells have been reported to express certain TLRs whose 
ligation may induce LSK cell expansion23–28, our results showed flagellin-induced stem and multipotent 
progenitor cell expansion to be independent of the expression of TLR5 on LSK cells themselves. 
Therefore, it may be surmised that flagellin-mediated irradiation protection may be reliant on certain 
soluble factors expressed by TLR5-bearing respondent cells or by cell contact between these cells and 
LSK cells. 
As hematopoiesis is a tightly regulated process whose dysregulation may result in life-threatening 
conditions, understanding the role of inflammatory signals (like flagellin) may prove to be important for 
understanding hematopoietic pathologies. In addition, it may be possible to design effective therapies that 
recapitulate this radioprotective effect or take advantage of specific arms of the response pathway without 
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the injection of a microbial product (flagellin). Such therapeutics many not only lend themselves for 
clinical use in cases of radiation poisoning, but may also be useful for mitigating off-target effects of 
radiation therapy. Unlike other TLR ligands with reported roles in hematopoiesis23–28, flagellin is a 
particularly attractive target, since its administration, even repeatedly, does not result in the overt 
inflammatory pathology associated with smaller amounts other ligands such as lipopolysaccharide (LPS).  
To build upon this study, it would be important determine whether flagellin’s effect upon bone 
marrow cells are mediated by soluble factors, or by cell contact. While we were unable to more precisely 
define the identity of these cells within the bone marrow, we have determined that BM neutrophils, 
among other cell types present in the bone marrow displayed the highest TLR5 expression at levels 
detectable by FACS analysis, we were however, unable to detect TLR5 expression on Lin- cells (data not 
shown). Further studies will be needed in order to identify this TLR5-respondent population. Comparing 
the transcriptional profile of flagellin-treated and untreated cells, may also be crucial to completely 
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